Evelo Biosciences Provides Clinical Updates
<!-- Name:DistributionId Value:8825641 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Evelo
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product…
<!-- Name:DistributionId Value:8756732 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business…
– Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end –– Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q…
Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of…
CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally…
Evelo Biosciences to Host KOL Discussion on Treatment Advances for All Stages of…
CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally…
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated…
Treatment with EDP1815 led to reduced production of cytokines IL-6, IL-8, and TNF in blood cellsCytokine analysis supports gut-restricted action of EDP1815 to resolve inflammation…
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing…
CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally…
Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis;…
–Clinically and statistically significant improvement in PASI-50 score achieved––EDP1815 safety and tolerability data comparable to placebo in study––EDP1815 advancing towards registration…